Filing Flows › Avalo Therapeutics (AVTX) › Stock forecast & fair value
Avalo Therapeutics (AVTX) stock forecast and fair value
Avalo Therapeutics (AVTX) trades at $13.65. 10 analysts' median price target is $38.50 (+182%), from $10.00 to $60.00. Across 10 valuation methods the middle fair value is $9.19 (-33%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $9.18 | $9.19 | $9.19 | -33% |
| EV/Sales vs peers, weighted | $9.18 | $9.19 | $9.19 | -33% |
| Residual income | $0.97 | $1.02 | $1.08 | -93% |
| Analysts' price targets | $10.00 | $36.60 | $60.00 | +168% |
| Tangible book (asset value) | $8.04 | $10.05 | $10.05 | -26% |
| Net cash (floor) | $8.26 | $9.18 | $9.18 | -33% |
| Survival-weighted value | $9.11 | $9.12 | $9.12 | -33% |
| Stage-weighted value (pre-revenue) | $8.37 | $9.43 | $9.43 | -31% |
| Combined forecast (3 months) | $11.18 | $14.19 | $17.59 | +4% |
| Net current asset value (net-net) | $5.59 | $8.39 | $8.39 | -39% |
Avalo Therapeutics' latest quarter
Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year), net loss $13.7M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for AVTX stock?
The median of 10 analysts' 12-month targets is $38.50, +182% from $13.65; the range is $10.00 to $60.00. The average rating is strong buy.
What is Avalo Therapeutics' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $1.02 and $36.60, with a middle value of $9.19 against a price of $13.65. Each method's assumptions are on the page.
Does Avalo Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is AVTX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.